InsiderTrades.com logo
Jonathan Wygant net worth and biography
  • Phone
  • Email
  • Website

Jonathan Wygant Biography and Net Worth

CAO of Veracyte

Jonathan Wygant is Chief Accounting Officer at Veracyte. He oversees all aspects of the company’s global accounting operations, financial reporting, and tax functions. Mr. Wygant has nearly 20 years of experience leading accounting operations for various healthcare and biotechnology companies. Prior to joining Veracyte in February 2022, he served as Corporate Controller at Biosplice Therapeutics, Inc., a clinical-stage biotechnology company, where he led all finance, accounting and reporting functions. Prior to that, Mr. Wygant was Chief Financial Officer at Cibus Global, LLC., an agricultural biotechnology company. He also served as Vice President, Controller and Chief Accounting Officer at Alere, Inc., a $2.5B point-of-care diagnostics company that was acquired by Abbott. Prior to that, Mr. Wygant served as Senior Vice President, Controller and Chief Accounting Officer at CareFusion, a $3.5B global medical technology and manufacturing company that was acquired by BD (Becton, Dickinson and Company). Mr. Wygant began his career in accounting with PricewaterhouseCoopers. He holds a Bachelor of Accountancy from the University of San Diego. 

What is Jonathan Wygant's net worth?

The estimated net worth of Jonathan Wygant is at least $1.21 million as of December 3rd, 2024. Mr. Wygant owns 40,270 shares of Veracyte stock worth more than $1,212,932 as of March 30th. This net worth evaluation does not reflect any other assets that Mr. Wygant may own. Learn More about Jonathan Wygant's net worth.

How old is Jonathan Wygant?

Mr. Wygant is currently 53 years old. There are 5 older executives and no younger executives at Veracyte. The oldest executive at Veracyte is Dr. Phillip G. Febbo M.D., Chief Scientific & Medical Officer, who is 58 years old. Learn More on Jonathan Wygant's age.

How do I contact Jonathan Wygant?

The corporate mailing address for Mr. Wygant and other Veracyte executives is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. Veracyte can also be reached via phone at (650) 243-6300 and via email at keith@veracyte.com. Learn More on Jonathan Wygant's contact information.

Has Jonathan Wygant been buying or selling shares of Veracyte?

Jonathan Wygant has not been actively trading shares of Veracyte in the last ninety days. Most recently, Jonathan Wygant sold 956 shares of the business's stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $43.36, for a transaction totalling $41,452.16. Following the completion of the sale, the chief accounting officer now directly owns 40,270 shares of the company's stock, valued at $1,746,107.20. Learn More on Jonathan Wygant's trading history.

Who are Veracyte's active insiders?

Veracyte's insider roster includes Bonnie Anderson (Insider), Muna Bhanji (Director), Rebecca Chambers (Exec. VP & CFO ), Rebecca Chambers (CFO), Karin Eastham (Director), Jens Holstein (Director), Evan Jones (Director), Giulia Kennedy (Insider), John Leite (Chief Commercial Officer, CLIA Business), Marc Stapley (CEO & Director), Jonathan Wygant (CAO), and Jonathan Wygant (CAO). Learn More on Veracyte's active insiders.

Are insiders buying or selling shares of Veracyte?

In the last year, insiders at the biotechnology company sold shares 17 times. They sold a total of 88,392 shares worth more than $2,810,829.26. The most recent insider tranaction occured on February, 3rd when CFO Rebecca Chambers sold 527 shares worth more than $23,108.95. Insiders at Veracyte own 1.3% of the company. Learn More about insider trades at Veracyte.

Information on this page was last updated on 2/3/2025.

Jonathan Wygant Insider Trading History at Veracyte

See Full Table

Jonathan Wygant Buying and Selling Activity at Veracyte

This chart shows Jonathan Wygant's buying and selling at Veracyte by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$200k-$100k$0$100k$200kTotal Insider BuyingTotal Insider Selling

Veracyte Company Overview

Veracyte logo
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
Read More

Today's Range

Now: $30.12
Low: $29.65
High: $31.07

50 Day Range

MA: $37.57
Low: $30.12
High: $46.14

2 Week Range

Now: $30.12
Low: $18.61
High: $47.32

Volume

710,014 shs

Average Volume

835,914 shs

Market Capitalization

$2.35 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.8